神経芽腫治療薬の世界市場

神経芽腫治療薬の世界市場は2030年までに11億米ドルに達する見込み

2023年に8億270万米ドルと推定された神経芽腫治療薬の世界市場は、2023-2030年の分析期間においてCAGR 5.1%で成長し、2030年には11億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである免疫療法は、CAGR 5.7％を記録し、分析期間終了時には6億1,680万米ドルに達すると予測されます。化学療法セグメントの成長率は、分析期間中CAGR 4.8％と推定されます。

米国市場は2億1,100万米ドルと推定、中国はCAGR 5.0％で成長予測

米国の神経芽腫治療薬市場は、2023年に2億1,100万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億8,310万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは5.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.9%と4.3%と予測されています。欧州では、ドイツがCAGR 4.0%で成長すると予測されています。

世界の神経芽腫治療薬市場- 主要動向と促進要因のまとめ

神経芽細胞腫は、主に幼児が罹患するがんの一種であり、身体のいくつかの部位に見られる未熟な神経細胞から発生します。神経芽腫の治療状況は、薬剤開発の進歩が治療成績の改善に極めて重要な役割を果たす中、長年にわたり大きく発展してきました。従来の治療法には、手術、放射線療法、化学療法などがありましたが、これらの治療法には大きな副作用が伴うことが多く、成功の程度も様々です。最近では、がん細胞の成長・増殖能力を直接阻害することを目的とした、より標的を絞った治療法へとシフトしてきています。このような標的療法のひとつに、ジヌツキシマブのようなモノクローナル抗体の使用があります。ジヌツキシマブは、神経芽腫細胞に見られるGD2ガングリオシドに結合し、免疫系による破壊の目印となります。その他の注目すべき薬剤としては、神経芽腫腫瘍に多く見られるALK遺伝子の変異を標的とするALK阻害剤や、がん細胞の分化と死滅を誘導するイソトレチノインなどの薬剤によるレチノイド療法があります。

標的療法に加えて、免疫療法も神経芽腫治療の有望な手段として浮上してきました。このアプローチは、身体の免疫システムを活用してがんと闘うもので、免疫チェックポイント阻害剤やCAR-T細胞療法などの薬剤が臨床試験で有望な結果を示しています。免疫チェックポイント阻害剤は、免疫系ががん細胞を攻撃するのを妨げるタンパク質をブロックすることによって作用し、CAR-T細胞療法は、がん細胞を認識して殺すように患者のT細胞を遺伝子改変するものです。これらの治療法は、選択肢が限られ、一般的に予後不良な高リスクまたは再発神経芽腫患者にとって特に有用です。さらに、最近のゲノミクスと個別化医療の動向は、神経芽腫腫瘍の遺伝子変化をより正確に同定することを可能にし、個々の患者の特異的な分子プロファイルに合わせた薬剤の開発を促進しています。

神経芽腫治療薬市場の成長は、神経芽腫の発生率の増加、認知度の向上と早期診断、革新的な薬剤のパイプラインの拡大など、いくつかの要因によってもたらされます。次世代シーケンシングや高度な画像診断技術などの診断技術の進歩により、早期発見率が大幅に向上し、よりタイムリーで効果的な介入が可能になりました。さらに、製薬会社や学術機関による研究開発への多額の投資により、新薬の発見と承認が加速しています。また、個別化医療が重視されるようになったことも、この市場の追い風となっています。個別化医療は、各患者のがん特有の遺伝子構成に合わせて治療法を調整することで、治療効果の向上と副作用の軽減を約束するものです。さらに、神経芽腫のような希少疾患に対する治療法の開発を促進するために、希少医薬品の指定や迅速な審査プロセスなどのインセンティブを提供する規制機関も増えています。最後に、患者擁護団体や非営利団体は、研究資金を提供し、一般の人々の認識を高める上で重要な役割を果たしており、神経芽腫の先進的な治療に対する需要をさらに促進しています。

調査対象企業の例（注目の86社）

• APEIRON Biologics AG
• Baxter International Inc.
• Bristol-Myers Squibb Company
• Cellectar Biosciences Inc.
• Clarity Pharmaceuticals
• Creative Biolabs
• Eli Lilly And Company
• Eugia US LLC
• Macrogenics Inc.
• Provectus Biopharmaceuticals, Inc.
• Recordati Group
• Sartorius AG
• United Therapeutics Corporation
• USWM, LLC.
• Y-mabs Therapeutics Inc.;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• その他の地域

第4章 競合

Global Neuroblastoma Drugs Market to Reach US$1.1 Billion by 2030

The global market for Neuroblastoma Drugs estimated at US$802.7 Million in the year 2023, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2023-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$616.8 Million by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$211.0 Million While China is Forecast to Grow at 5.0% CAGR

The Neuroblastoma Drugs market in the U.S. is estimated at US$211.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$183.1 Million by the year 2030 trailing a CAGR of 5.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.9% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Neuroblastoma Drugs Market - Key Trends and Drivers Summarized

Neuroblastoma is a type of cancer that primarily affects young children and arises from immature nerve cells found in several areas of the body. The treatment landscape for neuroblastoma has evolved significantly over the years, with advancements in drug development playing a pivotal role in improving outcomes. Traditional treatment methods have included surgery, radiation therapy, and chemotherapy, but these approaches often come with significant side effects and varying degrees of success. Recently, there has been a shift towards more targeted therapies, which aim to directly interfere with the cancer cells' ability to grow and proliferate. One such targeted therapy is the use of monoclonal antibodies, like dinutuximab, which binds to the GD2 ganglioside found on neuroblastoma cells, thereby marking them for destruction by the immune system. Other notable drugs include ALK inhibitors, which target mutations in the ALK gene often found in neuroblastoma tumors, and retinoid therapy with drugs like isotretinoin, which induces cancer cell differentiation and death.

In addition to targeted therapies, immunotherapy has emerged as a promising avenue for treating neuroblastoma. This approach leverages the body's immune system to fight cancer, with agents such as immune checkpoint inhibitors and CAR-T cell therapy showing encouraging results in clinical trials. Immune checkpoint inhibitors work by blocking proteins that prevent the immune system from attacking cancer cells, while CAR-T cell therapy involves genetically modifying a patient's T-cells to recognize and kill cancer cells. These therapies are particularly valuable for patients with high-risk or relapsed neuroblastoma, who have limited options and typically poor prognoses. Moreover, recent advancements in genomics and personalized medicine are enabling more precise identification of the genetic alterations in neuroblastoma tumors, facilitating the development of drugs tailored to the specific molecular profiles of individual patients.

The growth in the neuroblastoma drugs market is driven by several factors, including the increasing incidence of neuroblastoma, heightened awareness and early diagnosis, and the expanding pipeline of innovative drugs. Advances in diagnostic technologies, such as next-generation sequencing and advanced imaging techniques, have significantly improved early detection rates, allowing for more timely and effective interventions. Furthermore, substantial investments in research and development by pharmaceutical companies and academic institutions are accelerating the discovery and approval of new therapies. The market is also benefiting from a growing emphasis on personalized medicine, which promises to enhance treatment efficacy and reduce adverse effects by tailoring therapies to the unique genetic makeup of each patient's cancer. Additionally, regulatory agencies are increasingly offering incentives such as orphan drug designations and expedited review processes to encourage the development of treatments for rare diseases like neuroblastoma. Lastly, patient advocacy groups and non-profit organizations are playing a critical role in funding research and raising public awareness, further driving the demand for advanced neuroblastoma therapies.

Select Competitors (Total 86 Featured) -

• APEIRON Biologics AG
• Baxter International Inc.
• Bristol-Myers Squibb Company
• Cellectar Biosciences Inc.
• Clarity Pharmaceuticals
• Creative Biolabs
• Eli Lilly And Company
• Eugia US LLC
• Macrogenics Inc.
• Provectus Biopharmaceuticals, Inc.
• Recordati Group
• Sartorius AG
• United Therapeutics Corporation
• USWM, LLC.
• Y-mabs Therapeutics Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Neuroblastoma Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Pediatric Cancer Incidence Spurs Growth in Neuroblastoma Drug Development
  • Innovative Treatment Approaches Propel Growth in Neuroblastoma Drugs Market
  • Advancements in Immunotherapy Accelerate Demand for Neuroblastoma Treatments
  • Emerging Gene Therapy Technologies Strengthen Business Case for Novel Neuroblastoma Drugs
  • Precision Medicine Expands Addressable Market Opportunity for Targeted Neuroblastoma Therapies
  • Growing Awareness and Early Diagnosis Generate Demand for Effective Neuroblastoma Medications
  • Advancements in Biomarker Research Enhance the Business Case for Personalized Neuroblastoma Therapies
  • Rising Healthcare Expenditure Generates Opportunities in Neuroblastoma Drug Market
  • Focus on Quality of Life Improvements Spurs Demand for New Neuroblastoma Drug Therapies
  • Evolving Landscape of Combination Therapies Expands Addressable Market for Neuroblastoma Drugs
  • Technological Innovations in Drug Formulation Propel Neuroblastoma Treatment Advancements
  • Growing Interest in Orphan Drug Designations Generates Demand for Neuroblastoma Research
  • Advancements in Pharmacogenomics Strengthen Business Case for Tailored Neuroblastoma Therapies
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Neuroblastoma Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Neuroblastoma Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Neuroblastoma Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Injectables Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Injectables Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Injectables Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Offline Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Offline Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Offline Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Neuroblastoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: Canada 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: Canada 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
• JAPAN
  • Neuroblastoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: Japan 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: Japan 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 52: Japan 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
• CHINA
  • Neuroblastoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 53: China Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 55: China 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 56: China Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 58: China 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 59: China Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 61: China 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
• EUROPE
  • Neuroblastoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Neuroblastoma Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 64: Europe 16-Year Perspective for Neuroblastoma Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 67: Europe 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 70: Europe 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
• FRANCE
  • Neuroblastoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 74: France Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 75: France Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 76: France 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 77: France Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 79: France 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 82: France 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
• GERMANY
  • Neuroblastoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 83: Germany Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Germany Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 85: Germany 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 88: Germany 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 91: Germany 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 92: Italy Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Italy Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 94: Italy 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 97: Italy 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 100: Italy 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Neuroblastoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 101: UK Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 102: UK Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 103: UK 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 104: UK Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 106: UK 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 107: UK Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 109: UK 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Rest of Europe Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 112: Rest of Europe 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Rest of Europe Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 115: Rest of Europe 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Rest of Europe Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 118: Rest of Europe 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Neuroblastoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 120: Asia-Pacific Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 121: Asia-Pacific 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Asia-Pacific Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 124: Asia-Pacific 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Asia-Pacific Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 127: Asia-Pacific 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Rest of World Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 130: Rest of World 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 131: Rest of World Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Rest of World Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 133: Rest of World 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Rest of World Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 136: Rest of World 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030

IV. COMPETITION